文献速递神经肿瘤

接受激光间质热疗(LITT)与立体定向穿刺活检(SNB)的恶性脑肿瘤患者的再入院风险:基于国家再入院数据库(NRD)的协变量平衡权重分析

Readmission risk of malignant brain tumor patients undergoing laser interstitial thermal therapy (LITT) and stereotactic needle biopsy (SNB): a covariate balancing weights analysis of the National Readmissions Database (NRD).
PubMed 文献 · J Neurooncol · 2022-07-23

结果显示,LITT组与SNB组在30天或90天非计划再入院的 odds 上均无显著差异(所有 p≥0.177),加权分析结果一致(所有 p≥0.201),作者认为LITT的安全性特征得到支持。

要点

  • LITT与SNB两组患者的中位住院时长相当(LITT=2天[IQR 1,3] vs SNB=1天[IQR 1,2],p=0.820)。
  • 两组常规出院可能性无显著差异(p=0.263)。
  • 多变量调整后,LITT与SNB的30天或90天非计划再入院 odds 均无显著差异(所有 p≥0.177)。

核心结论

  • 恶性脑肿瘤患者接受LITT或SNB后的30天和90天再入院可能性相当,支持LITT作为恶性脑肿瘤治疗的安全性特征。

研究设计与样本

  • 再入院定义为非择期住院。
  • 采用调查回归方法和加权分析调整LITT与SNB队列间的人口学和临床差异。

主要发现

  • 研究期间,估计有685例恶性脑肿瘤患者接受择期LITT,15,177例接受择期SNB。
  • LITT组与SNB组的中位住院时长分别为2天(IQR 1,3)和1天(IQR 1,2),p=0.820。
  • 两组常规出院可能性无显著差异(p=0.263)。
  • 多变量调整后,LITT与SNB队列在30天或90天非计划再入院的 odds 上均无显著差异(所有 p≥0.177)。
  • 协变量平衡加权分析证实,LITT与SNB治疗患者的30天或90天再入院风险相当(所有 p≥0.201)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Despite procedural similarities between laser interstitial thermal therapy (LITT) and stereotactic needle biopsy (SNB), LITT induces delayed, pro-inflammatory responses not associated with SNB that may increase the risk of readmission within 30- or 90- days. Here, we explore this hypothesis. METHODS: We queried the National Readmissions Database (NRD, 2010-18) for malignant brain tumor patients who underwent elective LITT or SNB using International Classification of Diseases codes. Readmissions were defined as non-elective inpatient hospitalizations. Survey regression methods and a weighted analysis were utilized to adjust for demographic and clinical differences between LITT and SNB cohorts. RESULTS: During the study period, an estimated 685 malignant brain patients underwent elective LITT and 15,177 underwent elective SNB. Patients undergoing LITT and SNB exhibited comparable median lengths of hospital stay [IQR; LITT = 2 (1, 3); SNB = 1 (1, 2); p = 0.820]. Likelihood of routine discharge was not significantly different between the two procedures (p = 0.263). No significant differences were observed in the odds of 30- or 90-day unplanned readmission between the LITT and SNB cohorts after multivariable adjustment (all p ≥ 0.177). The covariate balancing weighted analysis confirmed comparable 30 or 90-day readmission risk between LITT and SNB treated patients (all p ≥ 0.201). CONCLUSION: The likelihood of 30- and 90-day readmission for malignant brain tumor patients who underwent LITT or SNB are comparable, supporting the safety profile of LITT as therapy for malignant brain cancers.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Do TH, Howard MA, Palzer EF, et al. Readmission risk of malignant brain tumor patients undergoing laser interstitial thermal therapy (LITT) and stereotactic needle biopsy (SNB): a covariate balancing weights analysis of the National Readmissions Database (NRD). J Neurooncol. 2022. PMID: 35871188. doi:10.1007/s11060-022-04093-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。